心血管手術設備的全球市場，市場規模和佔有率的分析 - 成長趨勢，預測(2025年～2033年)

心血管外科手術設備市場趨勢及總結

全球心血管手術器械市場規模預計將從 2024 年的 21.1 億美元增至 2033 年的 28.6 億美元，2025 年至 2033 年的複合年增長率為 3.45%。技術的快速進步、經濟高效的技術的日益普及以及對微創手術的需求不斷增長是該市場的主要驅動力。

推動心血管外科器械市場成長的因素

心血管疾病發生率不斷上升

心血管設備市場的主要成長動力之一是心臟衰竭和冠狀動脈疾病（CAD）等慢性心血管疾病的發生率不斷上升。冠狀動脈支架或心臟支架是最重要的心血管裝置之一。這些設備有助於治療心房顫動、冠狀動脈疾病、心臟病和動脈狹窄等致命的心臟病。心臟病發病率的上升推動了全球對先進心臟設備的需求。

根據美國疾病管制與預防中心（CDC）2023年11月發布的數據，2022年美國成年人中有4.9%被診斷出患有冠心病。此外，心血管疾病將在 2022 年導致 695,547 人死亡，成為美國第一大死因。世界衛生組織（WHO）估計，心臟病每年奪走1,790萬人的生命。

此外，市場擴張很大程度上歸功於監管機構對創新設備的批准不斷增加。在預測期內，市場可能會受到國家機構採取的眾多舉措的推動，這些舉措旨在使發展中國家更廣泛的人群能夠使用心血管設備。

增加獲得有效設備的機會

全球心臟病盛行率明顯上升，推動了對有效心臟裝置的需求。這些國家之所以採用新技術，是因為這些技術易於普及。為滿足新興市場對這些設備日益增長的需求而採取的措施也推動了市場的發展。此外，投資者也致力於增加中國、墨西哥和印度等國家獲得負擔得起的心血管設備的機會。因此，預計未來幾年它將佔據心血管設備市場的巨大佔有率。

例如，UltraLinQ Healthcare Solutions 在 2023 年 1 月的阿拉伯健康 2023 會議上推出了新的心臟監測解決方案。它是一個端到端的系統，使醫院和專科診所能夠為前往診所或在家中遠端存取的患者提供 Holter 服務。

微創技術的應用日益廣泛

推動市場擴張的主要因素之一是微創技術在心血管外科手術的應用日益廣泛。與開放式手術相比，微創技術具有許多優勢，包括使用複雜的影像、機器人輔助和更少的切口。患者可受益於更快的恢復時間、更少的不適、更少的感染機會和更少的併發症。由於患者偏好微創手術，對支架、導管和機器人手術器械等先進心血管設備的需求激增。此外，微創手術對患者和醫療保健專業人員具有吸引力，因為它可以更早出院、降低醫療成本並縮短治療時間。隨著微創心臟手術的趨勢和技術的不斷進步，心血管手術設備市場預計將進一步以更快的速度成長。

心血管外科市場的課題

設備成本高

該行業面臨的主要障礙之一是起搏器、支架和機器人手術工具等先進心血管設備的成本高昂。這些設備需要大量製造和研發投入，這增加了成本。這些成本障礙限制了這些設備的使用，特別是在醫療預算匱乏的中低收入地區。心血管護理方面的差異可能是由於某些地區的患者無法獲得最新、最有效的藥物。此外，即使結果有所改善，這些地區的醫療保健提供者也可能難以索取費用。製造商、政府和衛生系統必須考慮具有成本效益的替代方案、降價策略和創造性的融資方法，以改善獲取途徑並使這些技術更為廣泛地普及且價格更為實惠。

本報告研究了全球心血管外科設備市場，並提供了成長動力和課題、每個細分市場的分析以及關鍵公司的分析。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

• 成長促進因素
• 課題

第5章 心血管手術設備市場

第6章 市場佔有率

• 各產品類型
• 各用途
• 各終端用戶
• 各國

第7章 產品類型

• 心臟不停跳手術系統
• 人工心肺
• 心導管電氣燒灼術設備
• 拋棄式灌挪用品

第8章 用途

• 先天性心臟病
• 心律不整
• 冠狀動脈疾病
• 充血性心臟衰竭
• 其他

第9章 終端用戶

• 醫院
• 門診病人手術中心
• 其他

第10章 國家

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 比利時
  • 荷蘭
  • 土耳其
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 泰國
  • 馬來西亞
  • 印尼
  • 澳洲
  • 紐西蘭
• 南美
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東·非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第11章 波特的五力分析

第12章 SWOT分析

第13章 主要企業的分析

• Abbott Laboratories
• Boston Scientific Corporation
• Edwards Lifesciences
• Cardinal Health Inc.
• Medtronic PLC
• GE Healthcare
• LivaNova PLC
• Terumo Corporation

Cardiovascular Surgical Devices Market Trends & Summary

Cardiovascular Surgical Devices market is expected to reach US$ 2.86 billion by 2033 from US$ 2.11 billion in 2024, with a CAGR of 3.45% from 2025 to 2033. Rapid technological advancement, an increase in reasonably priced and efficient technologies, and growing demand for minimally invasive procedures are the primary factors propelling this market.

The report Cardiovascular Surgical Devices Market & Forecast covers by Product Type (Beating Heart Surgery Systems, Cardiopulmonary Bypass Equipment, Cardiac Ablation Devices, Perfusion Disposable), Application (Congenital Heart Defects, Cardiac Arrhythmia, Coronary Heart Disease, Congestive Heart Failure, Others), End-User (Hospitals, Ambulatory Surgical Centers, Others), Country and Company 2025-2033.

Cardiovascular Surgical Devices Industry Overview

The medical equipment and technologies used in the diagnosis, treatment, and management of heart-related illnesses, including arrhythmias, heart valve problems, and coronary artery disease, are the main focus of the cardiovascular surgical devices sector. Stents, heart valves, bypass grafts, pacemakers, defibrillators, and surgical tools are among the main goods. The growing incidence of cardiovascular diseases as a result of aging populations, sedentary lifestyles, and poor diets are some of the factors driving market expansion. Robotic-assisted operations and minimally invasive procedures are examples of technological advancements that have improved patient outcomes while cutting recovery times and medical expenses. Government funding, improvements in diagnostics, and growing healthcare awareness all support industry growth. High expenses, legal restrictions, and the demand for continuous clinical research to improve device efficacy and safety provide difficulties for the sector.

One of the most common illnesses in the world is cardiovascular disease. Cardiovascular disease (CVD) was the top cause of mortality in the United States in January 2024, accounting for 931,578 fatalities, more than all malignancies and chronic respiratory diseases combined, according to the American Heart Association. Cardiovascular devices are therefore essential for precisely identifying and treating heart conditions, which supports market growth. Rapid technological advancement, an increase in reasonably priced and efficient technologies, and growing demand for minimally invasive procedures are the primary factors propelling this market.

The market is expanding as a result of the rise in chronic cardiovascular disease cases. The need for cardiovascular devices has grown as a result of a rise in cardiovascular diseases. One of the most important cardiovascular devices is a heart or coronary artery stent. They make it easier to treat heart conditions such heart attacks, coronary disease, atrial fibrillation, and the growth of clogged arteries that are thought to pose a major risk to life. According to a WHO analysis from May 2024, cardiovascular diseases (CVDs) account for over 42.5% of all deaths in Europe each year, or almost 10,000 deaths per day, making them the leading cause of disability and early death. Men are over 2.5 times more likely than women to die from cardiovascular diseases (CVDs), and young people in Eastern Europe and Central Asia (ages 30-69) are at approximately five times the risk of dying from these diseases than their counterparts in Western Europe.

Growth Drivers for the Cardiovascular Surgical Devices Market

Increase in Cardiovascular Disease Prevalence

Plywood's In terms of expenses and medical services, the most common cause of patient growth is heart disease. One of the main factors driving the growth of the cardiovascular devices market is the increase in the prevalence of chronic cardiovascular illnesses like heart failure and coronary artery disease (CAD). Coronary or cardiac stents are among the most important cardiovascular devices. These devices aid in the treatment of potentially fatal cardiac problems, including atrial fibrillation, coronary heart disease, heart attacks, and constricted artery opening. The global need for sophisticated cardiac devices is increased by the frequency of cardiac disorders.

According to Centers for Disease Control and Prevention (CDC) data released in November 2023, 4.9% of adults in the United States received a coronary heart disease diagnosis in 2022. Additionally, cardiovascular illnesses account for 695,547 fatalities in 2022, making them the leading cause of death in the United States. The World Health Organization estimates that heart disease claims 17.9 million lives annually.

Furthermore, the market's expansion is significantly aided by the rise in regulatory bodies' approvals of innovative gadgets. The market will likely be guided over the forecast period by a number of efforts implemented by state bodies to make cardiovascular devices available to a broad population in developing regions.

Growing Accessibility of Effective Devices

The need for effective heart devices is fueled by the apparent rise in the prevalence of heart illnesses worldwide. The adoption of modern technology in these countries can be attributed to their accessibility. The market has also been stimulated by initiatives that have been implemented to meet the growing demand for these devices in emerging markets. Additionally, investors are concentrating on increasing the accessibility of affordable cardiovascular equipment in nations like China, Mexico, India, and others. In consequence, this is anticipated to draw a significant portion of the market for cardiovascular devices in the years to come.

For example, UltraLinQ Healthcare Solutions debuted a new cardiac monitoring solution at the Arab Health 2023 conference in January 2023. It has an end-to-end system that enables hospitals and specialty clinics to provide Holter services to patients who visit their clinics or who can be accessed remotely at home.

Rising Adoption of Minimally Invasive Techniques

One major factor propelling the market's expansion is the growing use of minimally invasive procedures in cardiovascular surgery. Compared to open operations, these techniques have a number of benefits, including the use of sophisticated imaging, robotic help, and fewer incisions. Patients gain from shorter recovery periods, less discomfort, a decreased chance of infection, and fewer complications. The need for sophisticated cardiovascular devices like stents, catheters, and robotic surgical instruments has surged as a result of patients' growing preference for minimally invasive operations. Furthermore, minimally invasive procedures are more appealing to patients and healthcare professionals since they enable faster hospital discharge, lower medical expenses, and shorter treatment durations overall. The market for cardiovascular surgical equipment is anticipated to grow even faster as a result of the trend toward minimally invasive cardiac procedures and ongoing technological advancements.

Challenges in the Cardiovascular Surgical Devices Market

High Cost of Devices

One major obstacle in the industry is the high cost of sophisticated cardiovascular equipment, such as pacemakers, stents, and robotic surgical instruments. The cost of these gadgets rises because they frequently need significant investment in manufacturing, research, and development. Their accessibility is restricted by this cost barrier, especially in areas with low and intermediate incomes where healthcare budgets are tight. Disparities in cardiovascular care may result from patients in certain areas not having access to the newest, most efficient medicines. Furthermore, even with better results, healthcare practitioners in these areas might find it difficult to defend the cost. Manufacturers, governments, and healthcare systems must investigate cost-effective substitutes, price-cutting tactics, and creative financing methods to increase access and make these technologies more generally accessible and reasonably priced.

Regulatory and Compliance Hurdles

The market for cardiovascular surgical devices is severely hampered by regulatory and compliance issues. New device approval is frequently a drawn-out procedure that necessitates comprehensive clinical trials to prove long-term results, safety, and effectiveness. Authorities like the FDA, EMA, or other national agencies have strict regulations that manufacturers must follow. These regulations differ depending on the region. These specifications may lengthen product launch schedules, postponing market entry and reducing potential profits. Development costs may also be raised by the price of carrying out clinical trials, obtaining required data, and satisfying regulatory requirements. These obstacles could hinder innovation, particularly for smaller businesses with fewer resources, and delay the adoption of ground-breaking innovations that could enhance cardiovascular care outcomes for patients.

Cardiac arrhythmia drives demand for devices like pacemakers and defibrillators

Cardiac arrhythmia is pivotal in the cardiovascular surgical devices market because of its prevalence and life-threatening implications. This spurs demand for modern solutions like pacemakers and catheter ablation structures. For instance, in 2024, Boston Scientific Corporation received FDA approval for the FARAPULSE(TM) Pulsed Field Ablation (PFA) System, offering a unique technique for treating drug-refractory, recurrent, symptomatic, paroxysmal atrial fibrillation.

United States Cardiovascular Surgical Devices Market

The high prevalence of cardiovascular diseases (CVDs), an aging population, and growing awareness of heart health are the main factors driving the United States' cardiovascular surgical devices industry, which is among the biggest and most developed in the world. Devices for arrhythmias, heart valve problems, and coronary artery disease, such as pacemakers, defibrillators, robotic surgical instruments, and stents, are important market segments. Technological developments that improve patient outcomes and shorten recovery times, such as bioresorbable devices and minimally invasive operations, are driving market expansion. The adoption of cutting-edge equipment is also made easier in the United States by its well-established healthcare infrastructure, government support, and high healthcare spending rate. High gadget costs, difficulties with regulations, and problems with reimbursement, however, continue to be commercial obstacles. The US continues to be a major force behind the development and marketing of cardiovascular devices worldwide.

An American Heart Association report from January 2024 states that around 2,552 fatalities in the United States are caused by CVD per day. Because of the substantial impact that CVD has on public health, there is an urgent need for efficient management and treatment options in the US market.

Abbott introduced the Abbott HeartMates program in October 2023 to help heart patients by allowing them to connect with others experiencing similar heart health concerns and share their stories. Professional football player Damar Hamlin served as the company's first ambassador at the beginning of the campaign under this program.

Germany Cardiovascular Surgical Devices Market

Due to its sophisticated healthcare system, elderly population, and high prevalence of cardiovascular diseases (CVDs), Germany is one of Europe's largest markets for cardiovascular surgical equipment. The adoption of sophisticated cardiovascular equipment, including as pacemakers, heart valves, stents, and surgical robots, is facilitated by the nation's robust reimbursement regulations and well-established medical infrastructure. Germany's emphasis on innovation, bolstered by a robust research and development environment, makes it easier to introduce innovative technology such as bioresorbable devices and minimally invasive procedures. The market is also growing as a result of the rising need for therapies for arrhythmias, heart failure, and coronary artery disease. Strict regulatory standards, the expensive cost of sophisticated gadgets, and rivalry from other European nations are some of the market's obstacles, nevertheless. Germany is nevertheless a major player in the global market for cardiovascular surgical devices in spite of these obstacles.

Data from a German registry for 2023, which included 168,841 cardiac and vascular surgeries in 77 institutions, was published in January 2024 by The Journal of Thoracic and Cardiovascular Surgery. The unadjusted in-hospital survival rates for 28,996 coronary artery bypass grafts, 39,859 cardiac valve surgeries, and 19,699 pacemaker/ICD implants were 97.6%, 97.7%, and 99.2%, respectively. In addition, 324 heart transplants and 2,982 extracorporeal life support treatments were carried out.

India Cardiovascular Surgical Devices Market

The increasing prevalence of cardiovascular diseases (CVDs) and improved access to healthcare are driving the market for cardiovascular surgical devices in India. Heart disease is becoming more prevalent in the nation as a result of aging populations, urbanization, and shifting lifestyles. Government programs, growing public awareness of heart health, and the development of healthcare infrastructure are important market drivers. Particularly in urban areas, there is a growing need for cardiovascular equipment such as heart valves, pacemakers, stents, and angioplasty instruments. Additionally, as doctors and patients look for better results and faster recovery periods, the use of minimally invasive procedures is increasing. However, obstacles including exorbitant equipment expenses, restricted reimbursement, and restricted availability in remote regions may prevent the industry from growing further. India continues to be a promising market for producers of cardiovascular devices in spite of these obstacles.

In the Indian state of Maharashtra, a decrease in the cost of coronary stents resulted in a 43.0% rise in the number of heart procedures performed, according a study conducted by the Harvard T.H. Chan School of Public Health (HSPH).

Saudi Arabia Cardiovascular Surgical Devices Market

Due to the high prevalence of cardiovascular diseases (CVDs) and significant healthcare investments, the market for cardiovascular surgical equipment is growing quickly in Saudi Arabia. An aging population, sedentary lifestyles, and changing lifestyles are the main causes of the Kingdom's rising heart disease rates. The government's Vision 2030 program, which aims to improve medical technology, expand access to high-quality care, and strengthen healthcare infrastructure, is driving up demand for sophisticated cardiovascular devices like heart valves, pacemakers, defibrillators, and stents. Furthermore, the industry is expanding more quickly due to consumers' increasing preference for minimally invasive procedures. Widespread adoption may be hampered by issues including exorbitant device costs, a lack of local manufacturing, and the requirement for specialized training for sophisticated treatments. Saudi Arabia is still a major Middle Eastern market for cardiovascular surgical devices in spite of this.

The BMC Cardiovascular Diseases article from March 2024 states that 1.6% of Saudi Arabians aged 15 and older had cardiovascular disease. This statistic shows the proportion of people in this age group who suffer from heart disease and other cardiovascular diseases of various kinds. The information highlights an important facet of the nation's health profile and sheds light on the prevalence of cardiovascular diseases among Saudi Arabians.

Cardiovascular Surgical Devices Market Segments

Product Type - Market breakup in 4 viewpoints:

1. Beating Heart Surgery Systems

2. Cardiopulmonary Bypass Equipment

3. Cardiac Ablation Devices

4. Perfusion Disposable

Application - Market breakup in 5 viewpoints:

1. Congenital Heart Defects

2. Cardiac Arrhythmia

3. Coronary Heart Disease

4. Congestive Heart Failure

5. Others

End-User - Market breakup in 3 viewpoints:

1. Hospitals

2. Ambulatory Surgical Centers

3. Others

Country - Market of 25 Countries Covered in the Report:

1. North America

• 1.1 United States
• 1.2 Canada

2. Europe

• 2.1 France
• 2.2 Germany
• 2.3 Italy
• 2.4 Spain
• 2.5 United Kingdom
• 2.6 Belgium
• 2.7 Netherland
• 2.8 Turkey

3. Asia Pacific

• 3.1 China
• 3.2 Japan
• 3.3 India
• 3.4 South Korea
• 3.5 Thailand
• 3.6 Malaysia
• 3.7 Indonesia
• 3.8 Australia
• 3.9 New Zealand

4. Latin America

• 4.1 Brazil
• 4.2 Mexico
• 4.3 Argentina

5. Middle East & Africa

• 5.1 Saudi Arabia
• 5.2 UAE
• 5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. Abbott Laboratories

2. Boston Scientific Corporation

3. Edwards Lifesciences

4. Cardinal Health Inc.

5. Medtronic PLC

6. GE Healthcare

7. LivaNova PLC

8. Terumo Corporation

Key Questions Answered in Report:

1. How big is the Cardiovascular Surgical Devices industry?

The global Cardiovascular Surgical Devices market size was valued at US$ 2.11 billion in 2024 and is expected to reach US$ 2.86 billion in 2033.

2. What is the Cardiovascular Surgical Devices growth rate?

The global Cardiovascular Surgical Devices market is expected to expand at a compound annual growth rate (CAGR) of 3.45% from 2025 to 2033.

3. Who are the key players in Cardiovascular Surgical Devices industry?

Some key players operating in the Cardiovascular Surgical Devices market includes Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences, Cardinal Health Inc., Medtronic PLC, GE Healthcare, LivaNova PLC, and Terumo Corporation.

4. What are the factors driving the Cardiovascular Surgical Devices industry?

Ageing populations, rising rates of heart disease, technological developments, minimally invasive procedures, government funding for healthcare, increased public awareness of healthcare issues, and the need for better patient outcomes and surgical efficiency are all factors driving the cardiovascular surgical devices market.

5. Which Region held the largest market share in the Cardiovascular Surgical Devices industry?

North America is expected to hold the largest market share in the industry.

6. What segments are covered in the Cardiovascular Surgical Devices Market report?

Product Type, Application, End User and Countries segment are covered in this report.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Cardiovascular Surgical Devices Market

6. Market Share

• 6.1 By Product Type
• 6.2 By Application
• 6.3 By End User
• 6.4 By Countries

7. Product Type

• 7.1 Beating Heart Surgery Systems
• 7.2 Cardiopulmonary Bypass Equipment
• 7.3 Cardiac Ablation Devices
• 7.4 Perfusion Disposable

8. Application

• 8.1 Congential Heart Defects
• 8.2 Cardiac Arrthymia
• 8.3 Coronary Heart Disease
• 8.4 Congestive Heart Failure
• 8.5 Others

9. End User

• 9.1 Hospitals
• 9.2 Ambulatory Surgical Centers
• 9.3 Others

10. Countries

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherland
  • 10.2.8 Turkey
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Thailand
  • 10.3.6 Malaysia
  • 10.3.7 Indonesia
  • 10.3.8 Australia
  • 10.3.9 New Zealand
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 Middle East & Africa
  • 10.5.1 Saudi Arabia
  • 10.5.2 UAE
  • 10.5.3 South Africa

11. Porter's Five Forces Analysis

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Rivalry
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threat

13. Key Players Analysis

• 13.1 Abbott Laboratories
  • 13.1.1 Overview
  • 13.1.2 Recent Development
  • 13.1.3 Revenue Analysis
• 13.2 Boston Scientific Corporation
  • 13.2.1 Overview
  • 13.2.2 Recent Development
  • 13.2.3 Revenue Analysis
• 13.3 Edwards Lifesciences
  • 13.3.1 Overview
  • 13.3.2 Recent Development
  • 13.3.3 Revenue Analysis
• 13.4 Cardinal Health Inc.
  • 13.4.1 Overview
  • 13.4.2 Recent Development
  • 13.4.3 Revenue Analysis
• 13.5 Medtronic PLC
  • 13.5.1 Overview
  • 13.5.2 Recent Development
  • 13.5.3 Revenue Analysis
• 13.6 GE Healthcare
  • 13.6.1 Overview
  • 13.6.2 Recent Development
  • 13.6.3 Revenue Analysis
• 13.7 LivaNova PLC
  • 13.7.1 Overview
  • 13.7.2 Recent Development
  • 13.7.3 Revenue Analysis
• 13.8 Terumo Corporation
  • 13.8.1 Overview
  • 13.8.2 Recent Development
  • 13.8.3 Revenue Analysis